Article

BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder.

Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canda.
Journal of psychiatry & neuroscience: JPN (Impact Factor: 6.24). 10/2008; 33(5):449-53.
Source: PubMed

ABSTRACT Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity and has been implicated in the affective disorders; studies have demonstrated elevated BDNF in patients taking lithium and other mood stabilizers. The objective of our study was to analyze BDNF in lithium-responsive patients with bipolar disorder (BD) to further understand the role of BDNF in the pathophysiology of BD.
Using enzyme-linked immunosorbent assay, we measured transformed B lymphocytes for BDNF protein.
BDNF levels were 36% lower in lymphoblasts from patients with BD (n = 12), compared with matched control participants (n = 13), and 55% lower when compared with their unaffected relatives (n = 14). Lithium significantly decreased BDNF levels in patients with BD and healthy control participants, although BDNF levels remained lower (33%) in the BD group posttreatment.
Decreased BDNF may constitute part of the pathophysiologic process of BD in a lithium-responsive subgroup of individuals with this disease. A compensatory mechanism protecting the genetically predisposed unaffected relatives from phenotypic expression of BD is suggested.

1 Bookmark
 · 
61 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial dysfunction, oxidative stress, and alterations in DNA methylation, are all associated with the pathophysiology of bipolar disorder (BD). We therefore studied the relationship between oxidative stress and DNA methylation in patients with BD with an excellent response to lithium treatment, their affected and unaffected relatives and healthy controls. Transformed lymphoblasts were cultured in the presence or absence of lithium chloride (0.75 mm). DNA and proteins were extracted from the cells to determine levels of 8-hydroxy-2-deoxyguanosine (8-OHdG), 5-methylcytosine (5-mc), mitochondrial complex I and glutathione peroxidase (GPx) activities. Methylation was decreased in BD subjects and their relatives compared to controls and remained so after lithium treatment in BD subjects but not in their relatives. 8-OHdG levels and complex I activity did not differ between groups before and after lithium treatment. Finally, relatives of patients showed increased GPx activity before and after lithium treatment, which negatively correlated with 5-mc levels. Changes in global methylation may be specific for BD and lithium may be involved in glutathione regulation. The present study supports the importance of DNA methylation to the pathophysiology of BD and the therapeutic potential of antioxidants in this illness.
    The International Journal of Neuropsychopharmacology 12/2013; · 5.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Relationship between neurotrophins, especially brain-derived neurotrophic factor (BDNF) and bipolar disorder (BPD) has been widely investigated, but results have been inconsistent. BDNF polymorphism may be associated with the susceptibility to subtype BPD such as rapid cycling BPD or early onset BPD. Met allele carriers of Val66Met of BDNF gene had smaller gray matter (GM) in both patients and healthy controls, but bipolar patients carrying Met allele had better response to lithium treatment. Decreased serum/plasma BDNF levels were observed at different mood states. BDNF may interact with other systems to execute its neuroprotective effects. Overall data suggest that neurotrophins may be involved in the pathogenesis of BPD and treatment response, but the magnitude of their role needs further investigation with large sample size studies.
    Expert Review of Neurotherapeutics 11/2013; · 2.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide. Although effective treatments for BD exist, variability in outcomes leads to a large number of treatment failures, typically followed by a trial and error process of medication switches that can take years. Pharmacogenetic testing (PGT), by tailoring drug choice to an individual, may personalize and expedite treatment so as to identify more rapidly medications well suited to individual BD patients.
    BMC medicine. 01/2014; 12(1):90.

Full-text (2 Sources)

View
9 Downloads
Available from
May 16, 2014